Source: Frontiers in Pharmacology. Unidade: ICB
Subjects: FARMACOLOGIA, CITOCINAS, DOR FACIAL, PROTEÍNAS QUINASES, ANSIOLÍTICOS, FÁRMACOS (SISTEMA NERVOSO CENTRAL)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Janaíne Prata de et al. Myrtenol reduces orofacial nociception and inflammation in mice through p38-MAPK and Cytokine inhibition. Frontiers in Pharmacology, v. 13, p. 1-8, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2022.910219. Acesso em: 01 nov. 2024.APA
Oliveira, J. P. de, Abreu, F. F., Bispo, J. M. M., Cerqueira, A. R. A., Santos, J. R. dos, Correa, C. B., et al. (2022). Myrtenol reduces orofacial nociception and inflammation in mice through p38-MAPK and Cytokine inhibition. Frontiers in Pharmacology, 13, 1-8. doi:10.3389/fphar.2022.910219NLM
Oliveira JP de, Abreu FF, Bispo JMM, Cerqueira ARA, Santos JR dos, Correa CB, Costa SKP, Camargo EA. Myrtenol reduces orofacial nociception and inflammation in mice through p38-MAPK and Cytokine inhibition [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-8.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3389/fphar.2022.910219Vancouver
Oliveira JP de, Abreu FF, Bispo JMM, Cerqueira ARA, Santos JR dos, Correa CB, Costa SKP, Camargo EA. Myrtenol reduces orofacial nociception and inflammation in mice through p38-MAPK and Cytokine inhibition [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-8.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3389/fphar.2022.910219